v3.26.1
License Agreement, Advances From Collaboration Partners, Legal and Other Contingencies - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 11, 2024
Oct. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2023
Jan. 03, 2025
Jul. 10, 2024
Aggregate milestone payment         $ 470,000,000          
Clinical and regulatory milestone payments received         3,600,000          
Patent expenses due to Harvard     $ 100,000 $ 100,000 100,000 $ 100,000        
Research and Development Arrangement [Member]                    
R&D grants received     0 0 $ 0 0        
Repayment percentage of grants received         100.00%          
Royalty received including accrued LIBOR interest     2,800,000   $ 2,800,000          
Technion Research and Development Foundation Ltd [Member]                    
Research and development expense               $ 100,000    
Award to fund development milestones         6,500,000          
Almirall License Agreement [Member]                    
Aggregate milestone payment $ 470,000,000                  
Almirall License Agreement [Member] | License and Service Revenue [Member]                    
Revenue from related party     0 0 0 0        
Cystic Fibrosis Foundation [Member]                    
Funding award amount received     0 0 0 0        
Royalty payment as percentage of net sales   1.00%                
Royalties   $ 300,000                
Unamortized debt discount     $ 300,000   300,000   $ 300,000      
Israel Innovation Authority [Member] | Research and Development Arrangement [Member]                    
R&D grants received         2,600,000          
Domicilium Term Loan [Member]                    
Aggregate principal amount of initial loan advance                   $ 3,200,000
Milestone payments       $ 500,000   $ 500,000     $ 500,000  
2025 CFF Award [Member] | Cystic Fibrosis Foundation [Member]                    
Value of the embedded derivative         $ 0   $ 0